Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study
Clinical trial NCT06482788 · RECRUITING
Trial details
- NCT number
- NCT06482788
- Sponsor
- Ruijin Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-22
- Primary completion
- 2025-05-31
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.